Gpi — Investor Presentation 2021

Oct 5, 2021

INVESTOR PRESENTATION OCTOBER 2021

Sustainability and the Health Care Market DIGITAL

Population ageing

• around 1/3 over 60 yo (Italy)
• general trend

Chronic diseases (NCDs¹ ) befall the world at large

• increasing prevalence of (multiple) chronic conditions
• increasing healthcare utilization
• increasing costs

40-50% has at least one NCD (well off countries)

• 70-80% of Health budget

From 2020 situation burdened with Covid-19

TRANSFORMATION

• Redesign processes
• Prevention and control of NCDs
• Integrate people, processes and structures
• Lessening costs, improving quality of life

SUSTAINABLE HEALTH SYSTEMS

Your Global Partner for a Better Future

We develop software, technologies and services to help innovating the models of care, assistance and prevention of the health care systems, optimizing processes and containing costs

A partnership to make health systems sustainable and help improve people's health and well -being

History of Growth

30 years of experience, management team with a track record of internal growth and M&As

International footprint

solutions used by 2,400 customers in more than 60 countries

Leadership

1st player in Italy: services granting access to care

2nd player in Italy: software solutions for healthcare and social systems

Uniqueness

integrated software, technology and service solutions to optimise the clinical, care, administrative and social processes.

Quality of life

our work helps improve the quality of life

a History of Steady Growth

2013 Orizzonte fund providing equity financing - First minibond issued.

2016 merger between GPI and the SPAC CFP1. Joining the stock market AIM Italia.

2018 graduated from AIM to MTA main market of Borsa Italiana.

€ 100 M M&A deals

*2018 EBITDA, net of extraordinary costs; 2019 EBITDA includes the effects of IFRS 16

Strategic Business Areas

TECHNOLOGIES 51.1%

Pay 3.3% Automation 4.4% ICT 5.5% Software 37.9%

SERVICES 48.9% Care

Notice: % revenue by SBA out of total revenue in FY 2020

Supply Lines

main SBAs

86.8% of total revenue

• hospital information system

• health social care
• blood transfusion & tissue bank
• health administration
• Business Intelligence, data analytics
• other
• BPO health care administrative svc. (AtC,..)
• telemedicine
• other
• Automation

Software

• automated pharmacy warehouse
• automated hospital pharmacy supply chain

other SBAs

13.2 % of totalrevenue

ICT

Pay

Care

• HW & SW on-site / on-line maintenance and assistance
• on-site / on-line system services
• e-payment and e-mandate solutions
• electronic storage

Actual Projects

Real answers to Covid- 19: concretely implementing the Group's vision

Virtual Care Region Lombardia

Telemedicine Software, wearables, technological and medical operational centre, services to monitor more than 55 thousand covid- or chronic-ill patients

Vaccination programme Region Valle d'Aosta

Artificial Intelligence,

consultancy, methodological innovation for the risk stratification and to prioritize the vaccine jabs based on demographic and clinical factors

Drive-in Swabs Region Lazio

Software solutions and devices for the queue management, ICT services and Contact Center services to improve the access to Covid diagnostic tests, reducing the waiting time from hours to minutes

Population Health Management Integrate the value of Persons with the value of Technologies.

Highlights

1H2021

• Contracts awarded as at 30 June ²⁰²¹€ 79 M Win ratio 48%
• Contract awarded Region Lazio Multichannel mgmt svc Servizio ReCUP (AtC) € 64.8 M | 2+2 years | Gpi 70%
• Contract awarded Region Tuscany Assistance, maintenance and lease svc for workstations in health organisations € 10.2 M | 4 years | Gpi 70% (Framework of up to € 34 M)

2H2021

• Proceeds from exercise of warrants € 22.3 M Funding M&As

Main M&As

FY2020

• Oslo Italia (Business Intelligence Health Care SW, Big Data & Analytics) | € 4.3 M Rev. | 30% EBITDA
• Umana Medical Technologies, Malta start up innovative solutions: nanomaterial tattoo sensors for remote monitoring
• Assets Haemonetics, USA (SW Blood Bank) \$ 11.3 M Rev. |35% EBITDA | 100 clients in the USA

1H2021

• Medinfo Group (SW Blood Bank) € 3.9 M Rev. | 36% EBITDA| 60 clients NHS UK, Army (France, Belgium)
• Hemasoft Software S.L. acquisition of the residual 40% of shares of Gpi's subsidiary

Solid Growth H1 2021

Revenue EBITDA +29.6% (22% organic) +35.2%

Revenue € 151.8 M thanks to the contribution of:

•	SW	€ 51.9 M	+25.0%	8.2% Org.
•	Care	€ 80.3 M	+31.7%	31.1% Org.
•	Other	€ 19.6 M	+33.7%	23.4% Org.

EBITDA: € 14.1 M | 10.2% on adj. Revenue

EBIT: € 2.5 M +1.6% vs H1 2020

after an increase in depreciation and amortisation of EUR 1.5 million compared to the previous period

Net Profit: € 0.2 M

improved results from operations offset the increase in net financial expenses and the positive tax impact of H1 2020

€M	H1 2021	H1 2020
Revenue & other income	151.8	117.2
Adjusted Revenue(1)	138.1	108.1
EBITDA	14.1	10.5
EBITDA % of adj. revenue	10.2%	9.7%
EBIT	2.5	0.9
Net profit	0.2	0.2

(1) Net of Temporary Joint Ventures (RTI)

Financial Highlights H1 2021

A3.1 CERVED Rating confirmed A- S&P |A3 Moody's | A-1 Fitch

€M	H1 2021	FY 2020 Restated
Net working capital	126.2	109.1
Non-current assets	167.7	158.4
Other operating assets/(liabilities)	(72.6)	(59.2)
NET INVESTED CAPITAL	221.6	208.2
Shareholders' equity	73.5	83.4
Net Financial Debt	148.1	124.8
TOTAL SOURCES	221.6	208.2

Net working capital

The increase in receivables is mainly linked to the increase in revenues due to the newly acquired companies

Shareholders' equity

Dividend distribution (€ 7.9 M) Related parties (€ 2.2 M minorities Riedl)

Net Financial Debt

• - Reflects the operating flows and the investment strategy of the Group in the H1 2020
• New ESMA Guideline No. 39. For consistency with the presentation, the corresponding value as at 31/12/2020 has also been recalculated.

Investments

Tot. € 29.5 M | M&A € 20.1 M | R&D € 4.5 M

*FY 2020 data - H-pub: public healthcare clients; H-Pri: private healthcare clients, NH-Pub: public non-healthcare clients; NH-Pri: private non-healthcare clients

Software

Revenues by Segment % on total SBA's revenue data as of 31/12/2020

Clinical Administrative Blood Transfusion

Human Resources

Business Intelligence

Other

Adj. Revenue €M EBITDA €M

Net of Temporary Joint Ventures (RTI)

Δ +25.0%

Δ +13.6%

*From FY 2020, the business of the subsidiary Xidera, which was included in the SBA Software, is now included in the SBA Care. FY 2019 was restated to reflect this change.

FY

2020

Care

Revenues by Segment % on total SBA's revenue data as of 31/12/2020

AtC - administr. svc. Telemedicine Other

Tenders win-ratio ** • 37%

Recurring fees

• 81%

Average contract length • 4-6 years

Average value of awards ('17-'20)

• € 24 M / year

Competitive position

• 1° player ITA

** Win ratio intended as % no. tenders won out of total bids .

FY 2020 data.

Adj. Revenue €M EBITDA €M

Net of Temporary Joint Ventures (RTI)

Δ +31.7%

H1 2021

FY

2020

Δ +9,3%

*From FY 2020, the business of the subsidiary Xidera, which was included in the SBA Software, is now included in the SBA Care. FY 2019 was restated to reflect this change.

6.1%

Other SBAs AUTOMATION

Automated warehouse sales, maintenance and service fees

• Retail Pharmacies
• Hospital Pharmacies

PAY

ePayment services POS rental and related software

• Large-scale Retail;
• Local PA
• Svc. providers based on POS
• System Integrator

ICT

Desktop management services fees other system services

• Healthcare customers
• Non-healthcare PA
• Other private customers

H1 2 0 2 0 H1 2 0 2 1

H1 2 0 2 0 H1 2 0 2 1

Δ

+62.8

%

Net of Temporary Joint Ventures (RTI)

Adj. Revenue €M EBITDA €M

Δ +19.4 %

Δ +46.5 %

15.1%

FY

2020

H1

2021

Competitive environment and strategic guidelines

Market Assessment Software and IT Services

Source: Gartner Hospital + Physician survey (2021 Q2)

value of the Global market for health care software + IT services in 2020

+7.3% 2020 on 2019	CAGR 20 –	24: 12.3%
50.5% North America	CAGR 20 –	24: 12.0%
24.8% Western Europe	CAGR 20 – 24:	11.0%

value of the Italian market for health care software + IT services in 2020 -0.4% 2020 on 2019

1.1% Italy CAGR 20 – 24: 6.7%

National Recovery and Resilience Plan

€ 5 B for digitizing health care of which € 1 B for Telemedicine

IT Market 2018 – 2024 (Italy)

Source:Netconsulting Cube (June 2021 Q2) - data in € M, %

TOTAL € 1,346.3 M CAGR 20-24 6.8% SW + Svc . € 1,091.3 M CAGR 20-24 6.9%

Competitive Ranking

Top Players in Italy

Software BPO AtC

Company	Brief description	Focus on HC	Ranking
	ICT solutions and related services for public and private healthcare providers.		1st
	ICT solutions, administrative and social-healthcare services for public and private healthcare providers.		2nd
	ICT solutions for the segments: finance, industry, telco&utilities and PA.	Through dedicated healthcare division	3rd
	Software for hospital processes, orders and risk management.	Reply's subsidiary	4th
	Digital transformation & ICT services for industries, energy, aerospace, healthcare, PA, etc.	Through dedicated healthcare division	5th

Adressable market ca. € 1 B Top 5 players ca. 35% of the market

> > 28 M cittadini serviti 29 M citizens reached

Company	Brief description	Ranking
	ICT solutions, administrative and social-healthcare services for public and private healthcare providers.	1st
	Maintenance services for medical devices, operative in 17 different countries.	n.a.
	BPO services (e.g. cleaning, security, logistics and healthcare services).	n.a.
	Local supplier of services for healthcare and the educational segment, operates in the Region of Veneto.	n.a.
	Local supplier of services for healthcare , operates in the Region of Lazio.	n.a.

Footprint in 70 Countries

Offices in 11 Countries

Blood Management System

strategic software for the Health Systems of all Countries Gpi is globally ranking among Top 5 providers Pro-forma earnings > € 20 M

Strategic intentions 2020-2024: the 5 pillars confirmed

Economic–Financial Targets Update for 2024

New targets estimated by equal scope of consolidation as of 31/12/2020

M&A Guidelines

M&A Guidelines Become a Major European Player

• Product Portfolio Evolution software|services| territories

• Structured software companies
• Product Portfolio Evolution Blood Management System Software

FUNDING SOURCES

• EXERCISED WARRANTS € 22.3 M
• BOND
• DEBT FINANCING

Investment Attractiveness

GPI IN THE STOCK MARKET

ISIN: IT0005221517 Ticker: GPI:IM 18,260,496 Ordinary Shares Price: € 12.05 4 October 2021 Capitalisation: € 220 M

Growth and Visibility

Leadership and Uniqueness

Technology and Service

Evolution of market/NRRP

M&A Opportunities

ANALYSTS' COVERAGE – Target price Midcap | Tp Icap 29 September 2021 € 18.00

Intermonte SIM 27 July 2021 € 17.00 Banca Akros 27 July 2021 € 15.20

SHAREHOLDING STRUCTURE

IR Contact details

Via Ragazzi del '99, 13 - 38123 Trento T +39 0461 381515 investor.relations@gpi.it

Fabrizio Redavid C. +39 335 1035499 fabrizio.redavid@gpi.it

Lorenzo Giollo

C. +39 340 8223333 lorenzo.giollo@gpi.it

Disclaimer

The material in this presentation was prepared by GPI S.p.A. ("GPI" or the "Company") without any form of independent verification; it is general, basic information about the current business of GPI as at the date of this presentation. This information is supplied in summary form and is not complete. This presentation is provided for information only and is not an offer or solicitation of an offer of purchase or sale of securities, nor shall there be any sale or purchase of securities in any jurisdiction in which such an offer, solicitation or sale should be illegal before the registration or qualification in accordance with the laws on securities of that jurisdiction. It is intended exclusively by way of a presentation to investors and is provided for information only. This presentation does not contain all information that may be relevant to an investor.

The information contained in this presentation, including the forecast financial information, must not be considered as advice or recommendations to investors or potential investors in connection with the holding, purchase or sale of securities or other products or financial instruments and does not take into account any specific investment targets nor the financial position. Before acting, it is important to consider the adequacy of information in relation to such subjects and, in particular, independent financial advice should be taken. All securities and product transactions or financial instruments entail risks, which include, amongst others, the risk of adverse or unforeseen market, financial or political developments and, in international transactions, the foreign exchange risk. The information contained in this presentation is confidential and is supplied to the user for information only and cannot be reproduced, re-sent or further distributed to anyone else, nor published, entirely or partly, for any purpose. This presentation is only distributed to and intended for: (A) persons in the European Economic Area Member States (excluding the United Kingdom), who are classed as "qualified investors" under Article 2, paragraph 1, letter e) of Directive 2003/71/EC (as amended and complete with any implementing measures applicable in each Member State); (B) in the United Kingdom, professional investment qualified investors coming under Article 19 (5) of the 2005 Order (financial promotion), the Order of Financial Services and markets and/or companies with high shareholders' equity and other persons to whom it can be lawfully disclosed, pursuant to Article 49,

paragraph 2, letters a) to d) of the Order; and (C) other persons to whom this presentation can be legally distributed and disclosed in accordance with applicable laws (all those pursuant to points (A) to (C) above, indicated as "relevant persons").

The information contained in this presentation may include forecasts. Although the Company believes it has a reasonable basis on which to make the forecasts given in this presentation, GPI warns that forecasts are no guarantee of future performance and that the effective operating results, financial conditions and conditions of liquidity and development of the segment in which GPI operates may differ considerably from those effectively achieved or suggested by the declarations given in this presentation or made by the GPI management team. Past performance is also not a reliable indication of future performance.

GPI makes no promise to update or publicly review the forecasts, even if new information is revealed or for any other reason. The information and opinions given in this presentation or in the declarations made by the GPI management team are given as at the date of this presentation or any other date, if indicated, and are subject to change without notice. Do not rely on the information given in this presentation for any purpose. No express or implicit declaration or guarantee is given by GPI, its subsidiaries or the respective consultants, functionaries, employees and agents, as regards the accuracy of information or opinions or for any loss as may derive directly or indirectly from any use of this presentation or its contents. This presentation is not intended for distribution or use by any person or entity that is a citizen or resident of a place, country or other jurisdiction in which such distribution, publication, availability or use may be in conflict with laws or regulations or which would require any registration or licence within such jurisdiction.

Blood Donor Centers Hospitals

ranks 5th on the global market pro-forma revenue ca \$ 26 M - 48% gross margin

GLOBAL COMPETITORS